In China, an expert consensus statement recognized ctDNA as an appropriate alternative for EGFR mutation testing, NSCLC subtype diagnosis, and treatment monitoring when tumor tissue biopsy is infeasible.12 Studies have shown that in ctDNA EGFR mutant patients treated with EGFR TKIs, ORR, PFS, and OS are similar to that in patients with EGFR mutations detected in tumors. This evidence concerns the gene EGFR and non-small cell lung carcinoma.